2′,6′-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine s-adenosyltransferase-2

Journal of Medicinal Chemistry

Volumn 57, Issue 14, 2014, Pages 6083-6091

  Sviripa, Vitaliy M ^a,c   Zhang, Wen ^a,d   Balia, Andrii G ^a,c   Tsodikov, Oleg V ^b   Nickell, Justin R ^b   Gizard, Florence ^b   Yu, Tianxin ^a,d   Lee, Eun Y ^d   Dwoskin, Linda P ^b   Liu, Chunming ^a,d   Watt, David S ^a,c,d  

^a Department of Molecular and Cellular Biochemistry ^*  (United States)

^b Department of Pharmaceutical Sciences College of Pharmacy   (United States)

^c Center for Pharmaceutical Research and Innovation   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' CHLORO 6' FLUOROSTYRYL) 5 (N,N DIMETHYLAMINO)PYRIDINE; 2 (2',6' DICHLOROSTYRYL) 5 (N,N DIMETHYLAMINO)PYRIDINE; 2 (2',6' DIFLUOROSTYRYL) 5 (N,N DIMETHYLAMINO)PYRIDINE; 2',6' DIHALOSTYRYLANILINE DERIVATIVE; 4 (2',6' DIFLUOROSTYRYL) N ETHYLANILINE; 4 (2',6' DIFLUOROSTYRYL) N,N DIMETHYLANILINE; 5 (2' CHLORO 6' FLUOROSTYRYL) 2 (N METHYLAMINO)PYRIDINE; 5 (2' CHLORO 6' FLUOROSTYRYL) 2 (N METHYLAMINO)PYRIMIDINE; 5 (2' CHLORO 6' FLUOROSTYRYL) 2 (N,N DIMETHYLAMINO)PYRIDINE; 5 (2' CHLORO 6' FLUOROSTYRYL) 2 (N,N DIMETHYLAMINO)PYRIMIDINE; 5 (2',6' DICHLOROSTYRYL) 2 (N METHYLAMINO)PYRIDINE; 5 (2',6' DICHLOROSTYRYL) 2 (N METHYLAMINO)PYRIMIDINE; 5 (2',6' DICHLOROSTYRYL) 2 (N,N DIMETHYLAMINO)PYRIDINE; 5 (2',6' DICHLOROSTYRYL) 2 (N,N DIMETHYLAMINO)PYRIMIDINE; 5 (2',6' DIFLUOROSTYRYL) 2 (N ETHYLAMINO)PYRIDINE; 5 (2',6' DIFLUOROSTYRYL) 2 (N ETHYLAMINO)PYRIMIDINE; 5 (2',6' DIFLUOROSTYRYL) 2 (N METHYLAMINO)PYRIDINE; 5 (2',6' DIFLUOROSTYRYL) 2 (N METHYLAMINO)PYRIMIDINE; 5 (2',6' DIFLUOROSTYRYL) 2 (N,N DIMETHYLAMINO)PYRIDINE; 5 (2',6' DIFLUOROSTYRYL) 2 (N,N DIMETHYLAMINO)PYRIMIDINE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; METHIONINE ADENOSYLTRANSFERASE; METHIONINE S ADENOSYLTRANSFERASE 2; POTASSIUM CHANNEL HERG; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MAT2A PROTEIN, HUMAN; STILBENE DERIVATIVE;

ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CANCER; STRUCTURE ACTIVITY RELATION; UPREGULATION; BIOCATALYSIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HEK293 CELL LINE; METABOLISM; PROTEIN SUBUNIT; SYNTHESIS; TUMOR CELL CULTURE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BIOCATALYSIS; CATALYTIC DOMAIN; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; METHIONINE ADENOSYLTRANSFERASE; MOLECULAR STRUCTURE; PROTEIN SUBUNITS; PYRIDINES; PYRIMIDINES; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84905001693     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5004864     Document Type: Article

References (23)

1. Zhang, W.; Sviripa, V.; Kril, L. M.; Chen, X.; Yu, T.; Shi, J.; Rychahou, P.; Evers, B. M.; Watt, D. S.; Liu, C. Fluorinated N, N -dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression J. Med. Chem. 2011, 54, 1288-1297
2. Zhang, W.; Sviripa, V.; Chen, X.; Shi, J.; Yu, T.; Hamza, A.; Ward, N. S.; Kril, L. M.; Vander Kooi, C. W.; Zhan, C.-G.; Evers, B. M.; Watt, D. S.; Liu, C. Fluorinated N, N -dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A ACS Chem. Biol. 2013, 8, 796-803
3. Watt, D. S.; Liu, C.; Sviripa, V.; Zhang, W. Stilbene analogs and methods of treating cancer. Patent US2012/0196874, August 2, 2012.
4. Paul, S.; Mizuno, C. S.; Lee, H. J.; Zheng, X.; Chajkowisk, S.; Rimoldi, J. M.; Conney, A.; Suh, N.; Rimando, A. M. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer Eur. J. Med. Chem. 2010, 45, 3702-3708
5. Orsini, F.; Sello, G. Natural stilbenes and analogues as antineoplastic agents Stud. Nat. Prod. Chem. 2008, 34, 77-127
6. Maccario, C.; Savio, M.; Ferraro, D.; Bianchi, L.; Pizzala, R.; Pretali, L.; Forti, L.; Stivala, L. A. The resveratrol analog 4,4′-dihydroxy-trans- stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells Carcinogenesis 2012, 33, 2172-2180
7. Mikuła-Pietrasik, J.; Sosińska, P.; Wierzchowski, M.; Piwocka, K.; Ksia̧żek, K. Synthetic resveratrol analogue, 3,3′,4,4′,5,5′-hexahydroxy- trans -stilbene, accelerates senescence in peritoneal mesothelium and promotes senescence-dependent growth of gastrointestinal cancers Int. J. Mol. Sci. 2013, 14, 22483-22498
8. Chae, Y. S.; Kim, J. G.; Jung, H. J.; Yang, J. D.; Jung, J. H.; Aiyar, S. E.; Kim, S.; Park, H. Anticancer effect of (E)-2-hydroxy-3′,4′, 5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization Cancer Chemother. Pharmacol. 2011, 68, 349-358
9. Kelkel, M.; Jacob, C.; Dicato, M.; Diederich, M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies Molecules 2010, 15, 7035-7074
10. Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer Drug Discovery Today 2010, 15, 757-765
11. Cai, J.; Sun, W. M.; Hwang, J. J.; Stain, S. C.; Lu, S. C. Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance Hepatology 1996, 24, 1090-1097
12. Chen, H.; Xia, M.; Lin, M.; Yang, H.; Kuhlenkamp, J.; Li, T.; Sodir, N. M.; Chen, Y. H.; Josef-Lenz, H.; Laird, P. W.; Clarke, S.; Mato, J. M.; Lu, S. C. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells Gastroenterology 2007, 133, 207-218
13. Ito, K.; Ikeda, S.; Kojima, N.; Miura, M.; Shimizu-Saito, K.; Yamaguchi, I.; Katsuyama, I.; Sanada, K.; Iwai, T.; Senoo, H.; Horikawa, S. Correlation between the expression of methionine adenosyltransferase and the stages of human colorectal carcinoma Surg. Today 2000, 30, 706-710
14. Liu, Q.; Chen, J.; Liu, L.; Zhang, J.; Wang, D.; Ma, L.; He, Y.; Liu, Y.; Liu, Z.; Wu, J. The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production J. Biol. Chem. 2011, 286, 17168-17180
15. Kumar, D.; Elliott, P. Principles and Practice of Clinical Cardiovascular Genetics; Oxford University Press: New York, 2010.
16. Shafqat, N.; Muniz, J. R. C.; Pilka, E. S.; Papagrigoriou, E.; von Delft, F.; Oppermann, U.; Yue, W. W. Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits Biochem. J. 2013, 452, 27-36
17. Maryanoff, B. E.; Reitz, A. B. The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism, and selected synthetic aspects Chem. Rev. 1989, 89, 863-927
18. Hageman, H. A. The von Braun cyanogen bromide reaction Org. React. 1953, 7, 198-262
19. A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery; Chen, T., Ed.; CRC Press: Boca Raton, FL, 2010.
20. Biswas, T.; Resto-Roldán, E.; Sawyer, S. K.; Artsimovitch, I.; Tsodikov, O. V. A novel non-radioactive primase-pyrophosphatase activity assay and its application to the discovery of inhibitors of Mycobacterium tuberculosis primase DnaG Nucleic Acids Res. 2013, 41, e56
21. Greengrass, P. M.; Stewart, M.; Wood, C. M. Affinity-assay for the human ERG potassium channel. Patent WO2003021271 A2, March 13, 2003.
22. + channel by the antidepressant drug amitryptyline Br. J. Pharmacol. 2000, 129, 1474-1480
23. Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 2003, 58, 32-45